Aligos Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
About Aligos Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections. Its drug development pipeline targets conditions such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. Key drug candidates in development include pevifoscorvir sodium for chronic HBV infection, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections. The company’s potential customers and end users include patients suffering from viral infections and liver disorders, as well as collaboration and licensing partners such as Xiamen Amoytop Biotech Co., Ltd.
The company operates clinical development programs across multiple global jurisdictions, conducting studies in the United States and internationally, including clinical and preclinical collaboration rights in China, Taiwan, Hong Kong, and Macau. Aligos Therapeutics maintains its principal executive offices and headquarters in South San Francisco, California.
Summary of the business section of Aligos Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aligos Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- One Corporate Dr., 2nd Floor 94080
- Phone
- (800) 466-6059
- Employees
- 82, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- ALGS
- Exchange
- Nasdaq
- IPO date
- Oct 19, 2020
- Shares outstanding
- 12M, Aug 3, 2026
- Public float
- $19.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 19, 2024; 1-for-25 reverse, Aug 19, 2024
- SEC CIK
- 1799448
- CUSIP
- 01626L204
- ISIN
- US01626L2043
- LEI
- 549300UU2UJIKJYX0S67
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lawrence Blatt | President and CEO, Director | 1,866,092 |
| Nikhil Aneja | Principal Accounting Officer | – |
| Julian A. Symons | See Remarks | 394,064 |
| Lesley Ann Calhoun | See Remarks | – |
| Margarita Chavez | Director | – |
| James Paul Scopa | Director | 183,083 |
| Carole Nuechterlein | Director | 11,025,941 |
| Heather Preston | Director | – |
| Bridget A. Martell | Director | – |
| Peter Hirth | Director | 59,549 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 82 full-time employees, including 64 employees engaged in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 31, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 22, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 7, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 19, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |